EcoDrugPlus

Hck Proto-Oncogene, Src Family Tyrosine Kinase

Ensembl ID : ENSGMOG00000018342
Gene Symbol: HCK
3 Cross references
202 Possible Orthologues:

Il2 Inducible T Cell Kinase

Ensembl ID : ENSGMOG00000013813
Gene Symbol: ITK
3 Cross references
206 Possible Orthologues:

Imp (Inosine 5'-Monophosphate) Dehydrogenase 1a

Ensembl ID : ENSGMOG00000007073
Gene Symbol: IMPDH1A
2 Cross references
258 Possible Orthologues:

Imp (Inosine 5'-Monophosphate) Dehydrogenase 2

Ensembl ID : ENSGMOG00000019271
Gene Symbol: IMPDH2
3 Cross references
200 Possible Orthologues:

Janus Kinase 1

Ensembl ID : ENSGMOG00000003132
Gene Symbol: JAK1
3 Cross references
212 Possible Orthologues:

Janus Kinase 2a

Ensembl ID : ENSGMOG00000016634
Gene Symbol: JAK2A
1 Cross references
199 Possible Orthologues:

Kras Proto-Oncogene, Gtpase

Ensembl ID : ENSGMOG00000010581
Gene Symbol: KRAS
2 Cross references
207 Possible Orthologues:

Lyn Proto-Oncogene, Src Family Tyrosine Kinase

Ensembl ID : ENSGMOG00000004746
Gene Symbol: LYN
3 Cross references
195 Possible Orthologues:

Mapk Activated Protein Kinase 2

Ensembl ID : ENSGMOG00000014838
Gene Symbol: MAPKAPK2
3 Cross references
187 Possible Orthologues:

Mapk Activated Protein Kinase 5

Ensembl ID : ENSGMOG00000007433
Gene Symbol: MAPKAPK5
2 Cross references
179 Possible Orthologues:

Mapk Interacting Serine/threonine Kinase 2b

Ensembl ID : ENSGMOG00000011105
Gene Symbol: MKNK2B
3 Cross references
208 Possible Orthologues:

Met Proto-Oncogene, Receptor Tyrosine Kinase

Ensembl ID : ENSGMOG00000008433
Gene Symbol: MET
1 Cross references
205 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).